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Aim To indirectly compare rivaroxaban and dabigatran for 
prevention of venous thromboembolism (VTE) after total 
hip or knee arthroplasty (THA, TKA) based on their pivotal 
efficacy/safety trials embracing a total of 20 618 patients.
Methods Pooled risk differences (RD) for rivaroxaban vs 
enoxaparin and dabigatran vs enoxaparin obtained from 
separate meta-analyses of two sets of trials were used to 
indirectly estimate RDs for rivaroxaban vs dabigatran.
Results Primary efficacy (any VTE+all-cause mortality) 
and safety (major bleeding) outcomes in enoxaparin arms 
largely differed across similarly designed rivaroxaban and 
dabigatran trials (differences in venography adjudica-
tion and bleeding events definitions). However, incidence 
of symptomatic VTE and incidence of major/non-major 
clinically relevant bleeding (including surgical site) were 
consistent in this respect. RDs (as percentages) for symp-
tomatic VTE were: rivaroxaban-enoxaparin = -0.4% (95% 
confidence interval [CI], -0.9 to 0.05); dabigatran-enoxapa-
rin = -0.09% (95% CI, -1.0 to 0.8); rivaroxaban-dabigatran = -
0.3% (95% CI, -1.3 to 0.7; P = 0.275). RDs for major/clinically 
relevant bleeding were rivaroxaban-enoxaparin = 0.99% 
(95%CI, 0.29 to 1.69); dabigatran-enoxaparin = 0.02% (95% 
CI, -1.0 to 1.0); rivaroxaban-dabigatran = 0.97 (95% CI, -0.43 
to 2.37; P = 0.085). Mortality rates (all-cause, VTE-related, 
bleeding-related) were very low not indicating differences 
between any two of the three treatments.
Conclusion Methodological differences disable indirect 
comparisons of rivaroxaban vs dabigatran that would be 
based on major efficacy/safety outcomes of their pivotal 
trials. The two drugs do not seem to differ regarding in-
cidence of symptomatic VTE. Risk of a relevant bleeding 
is higher with rivaroxaban than with enoxaparin and the 
same tendency exists also vs dabigatran. Direct rivaroxa-
ban vs dabigatran comparisons in this setting are needed.
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Total hip and knee arthroplasty (THA and TKA, respectively) 
are common, routine and effective treatments for a num-
ber of conditions affecting the two joints. However, treat-
ed patients are at a high risk of venous thromboembolism 
(VTE), ie, deep venous thrombosis (DVT) potentially result-
ing in a fatal pulmonary embolism (PE) or other sequelae 
(pulmonary hypertension, postthrombotic syndrome). For-
tunately, the prevailing form of the post-arthroplasty DVT, 
distal DVT, is rarely associated with PE, but the more omi-
nous proximal DVT may also occur (1-3). Hence, thrombo-
prohylaxis is indicted for all patients undergoing THA/TKA, 
but choice of the means is still controversial because treat-
ments that effectively prevent VTE (primarily anticoagu-
lants) simultaneously increase the risk of bleeding (3). The 
prevailing form is surgical site bleeding that might require 
further interventions (revision, re-operation, transfusion) 
and/or compromise functional outcomes. Extra-surgical 
site bleedings are less common but might be critical by lo-
calization (intracranial, intraorbital, retroperitoneal) and/or 
extent, have sequelae, or be fatal (4).
Rivaroxaban (a direct factor Xa inhibitor) and dabigatran 
etexilate (dabigatran, a direct thrombin inhibitor) are new 
generation oral anticoagulants. In the European Union, 
both drugs are approved as effective and acceptably safe 
in prevention of VTE after THA/TKA (5,6) based on pivotal 
trials (7-13), in which they were compared with enoxapa-
rin, a low molecular weight heparin preparation. Inherent-
ly, they also increase bleeding tendency but provide the 
convenience of simple dosing (orally, once daily), predic-
tive effects not requiring routine coagulation monitoring, 
and low potential for drug interactions (5,6). Although the 
two drugs have never been compared directly, an analy-
sis suggested (14) that rivaroxaban could be more cost-
effective than dabigatran due to supposedly better ef-
ficacy and lower rate of major bleedings (primary safety 
concern). However, the analysis (14) referred only to some 
(and not all) of the pivotal rivaroxaban and dabigatran tri-
als. Furthermore, it used enoxaparin data from a single ri-
varoxaban trial as a reference for assessment of both rivar-
oxaban and dabigatran in THA, and enoxaparin data from 
a single dabigatran trial as a reference for assessment of 
both drugs in TKA. Two recent reports demonstrated that 
“mixing” data from different thromboprophylaxis trials in 
THA/TKA setting in such a manner might not be an ap-
propriate procedure. First, different definitions of “bleeding 
events” have been used in different trials (4). Second, ma-
jor efficacy outcomes include counting of, among others, 
asymptomatic venographically detected VTE based on 
adjudication. Although the process is standardized, 
actual event rates in individual trials are largely influenced 
by the factor “adjudication committee” (15). Therefore, we 
considered it worthwhile to evaluate whether the exist-
ing pivotal trials allowed for indirect assessment of relative 
efficacy/safety of rivaroxaban vs dabigatran in prevention 
of VTE after THA/TKA and whether any of the two drugs 
should be considered superior to the other one.
MaTeRials and MeThods
adjusted indirect comparison between treatments
Two treatments (A and B) can be compared indirectly based 
on their individual comparisons with a common control 
treatment (C). The treatment effect of A vs B (TAB) is derived 
from treatment effects of A vs C (TAC) and B vs C (TBC) and the 
procedure is termed adjusted indirect comparison (16,17). 
Computationally (18), TAB = TAC – TBC, standard error (SE) of 
TAB = √[SE(TAC)
2 + SE(TBC)
2], and z-statistic is used to test the 
null hypothesis TAB = 0. If there are several A/C and B/C trials, 
TAC and TBC are derived from appropriate meta-analyses. Ad-
justed indirect comparisons (A vs B) based on meta-analy-
ses (of A vs C and B vs C) perform well and provide unbi-
ased estimates of TAB (16,17). The basic condition is that A/C 
and B/C trials are reasonably similar in design (setting, pa-
tient characteristics, outcome definitions) and in regard to 
results for the reference treatment. Also, sets of A/C and B/C 
trials should be appropriate for meta-analysis (16,17).
data acquisition and evaluation
Published reports on pivotal rivaroxaban (7-10) and dabig-
atran (11-13) trials for prevention of VTE after THA/TKA and 
related documents made public by regulatory agencies 
(European Medicines Evaluation Agency, EMEA; Food and 
Drug Administration, FDA) (5,6,19,20) were retrieved and 
reviewed. Considering the regulatory requirements (21), it 
was expected that rivaroxaban and dabigatran trials would 
be fairly comparable in design, use of the reference treat-
ment, and patient characteristics. To assess feasibility of 
the major (primary) efficacy and safety outcomes (bleed-
ing events) for indirect comparisons, their definitions and 
results for enoxaparin arms were compared across cor-
responding rivaroxaban and dabigatran trials. Other out-
comes were also assessed in order to identify retrievable 
data that would be appropriate for indirect comparisons. 
Incidence of symptomatic VTE on treatment (includes DVT 
and/or PE, fatal or not; denominator: patients who under-
went surgery and received at least one dose of study drug) 
was reported in all trials and was considered informative of 
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efficacy, practically relevant – in practice, venograms and 
other evaluations are typically undertaken when indicated 
by clinical signs and symptoms – and likely not affected 
by adjudication. A document supplied by the rivaroxa-
ban sponsor to the FDA (19) provided data on surgical site 
bleedings that were not explicitly listed in the published re-
ports on rivaroxaban trials (7-10). This allowed that a com-
posite outcome incidence of major or non-major clinically 
relevant bleeding on treatment be retrieved from all trials 
and used as a measure of safety (definition of “major” and 
“non-major clinically relevant” was identical in all trials, but 
now it included both surgical site and extra-surgical site 
events; denominator: patients who received at least one 
dose of study drug). Data on all-cause mortality during tri-
al, bleeding-related mortality on treatment (denominator: 
patients who received at least one dose of study drug) and 
VTE-related mortality on treatment (denominator: patients 
who received at least one dose of study drug and under-
went surgery) were also retrieved.
analysis and data presentation
Dabigatran was used at two dose levels: 220 mg or 150 mg 
once daily (11-13). Since the efficacy and safety outcomes 
were practically identical for the two doses, all analyses of 
dabigatran trials were based on pooled dabigatran data.
Incidence of symptomatic VTE on treatment and incidence 
of major or non-major clinically relevant bleeding on treat-
ment met the criteria for indirect comparisons. Random-
effects meta-analysis was conducted on each outcome 
separately for the rivaroxaban (7-10) and dabigatran (11-
13) trials to obtain pooled treatment effects of each drug 
vs enoxaparin. Risk difference was used as an effect mea-
sure since it was used in the original individual trials (7-13). 
Cochran Q and I2 statistic were used as indicators of het-
erogeneity (inconsistency) of trial results. Pooled estimates 
were then used to calculate rivaroxaban vs dabigatran risk 
differences, as explained. In the indirect comparison, dabi-
gatran was perceived as a “reference” due to the fact that 
dabigatran trials (11-13) chronologically preceded the ri-
varoxaban trials (7-10). All risk differences were low, with 
2-4 decimal places. To improve their interpretability, ben-
efit or harm per 1000 treated patients were employed as 
more intuitive measures. For example, for incidence of VTE, 
for which risk reduction is beneficial and represents a ther-
apeutic effect, risk difference (RD) between a test (T) and 
a reference (R) treatment (T-R) with a minus sign “favors” 
T treatment, say RD (T-R) = -0.005 (95% confidence inter-
val [CI], -0.009 to -0.001); T provides benefit over R, since 
fewer patients experience VTE. Multiplication by 1000 indi-
cates that “fewer patients” means 5 per 1000, and removal 
of the minus sign (requiring that the upper and the low-
er CI limits “switch places”) results in benefit per 1000 pa-
tients = 5 (95% CI, 1 to 9). This is interpreted as: for 1000 
patients treated with T instead of R, between 1 and 9, and 
most likely 5 additional would benefit by avoiding VTE. If CI 
embraces 0 eg, RD = -0.005 (95% CI, -0.013 to 0.003), 95% 
CI around benefit per 1000 patients extends from benefit 
to harm (13 benefit to 3 harm): for 1000 patients treated 
with T instead of R, most likely 5 additional (and up to 13) 
would benefit by avoiding VTE, however, it could also be 
that up to 3 more would be harmed by experiencing it. 
For incidence of bleeding for which higher risk is harmful 
and represents an adverse effect, RD (T-R) is converted into 
harm per 1000 patients. Benefit or harm per 1000 patients 
is rounded to the nearest integer.
Mortality was very low in all trials and most treatment arms 
had 0 events rendering them impractical for meta-analy-
sis. Instead, event rates were summarized by treatment and 
by setting (THA, TKA) which were treated as strata. Using 
enoxaparin-treated patients as “standard population,” two 
“test populations” (rivaroxaban, dabigatran) were evaluated 
by calculating standardized mortality ratios (SMR). SMR is 
an adjusted relative risk that relates test (rivaroxaban, dabi-
gatran) population to the standard population. When two 
SMRs (relative risks) are derived from similarly structured 
populations and use the same standard, they can be com-
pared as a ratio of two SMRs to provide information about 
the relationship between the two test populations. Howev-
er, two test populations are more explicitly related to each 
other through a ratio of their directly standardized event 
rates, ie, standardized rate ratio (SRR). Just as SMR, SRR is an 
adjusted relative risk. SMR and SRR are based on number of 
events per observed person-time. VTE-related and bleed-
ing-related mortalities were reported for the period “during 
treatment” (7-13). Regardless of the treatment (rivaroxaban, 
dabigatran, enoxaparin), treatment period in thrombopro-
phylaxis after THA/TKA is defined by the setting: 4-5 weeks 
after THA and 8-15 days after TKA (1-3). Consequently, dura-
tion of treatment for the setting was considered a “unit of 
person-time” and the number of person-time units equaled 
the number of patients. All-cause mortality was reported for 
the “entire study period” ie, treatment period + a follow-up 
period. SMR and SRR were first calculated using the “entire 
study period” as a unit of person-time. However, rivaroxa-
ban trials (7-10) had shorter follow-up periods (30-35 days 
after the last dose, ie, till day 45-60 after surgery) than 
dabigatran trials (11-13) (2 months after the last dose, 
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ie, till day 75-90 after surgery). Mortality (all-cause) between 
days 60 and 90 after total joint replacement was repeated-
ly shown to correspond to 1/4 of the cumulative mortality 
during the first 60 days after the surgery (22,23). Hence, to 
correct for the imbalance in follow-up periods, number of 
deaths observed in the rivaroxaban arms and enoxaparin 
arms from rivaroxaban trials was increased by 25% to yield 
“corrected all-cause mortality” and SMR and SRR were calcu-
lated again. We used StatsDirect statistical software (StatsDi-
rect Ltd, Altrincham, UK).
ResulTs
Characteristics of the pivotal rivaroxaban and 
dabigatran trials and feasibility of indirect comparisons 
based on major reported outcomes
There were 4 pivotal rivaroxaban trials (2 in THA, 2 in TKA) 
and 3 pivotal dabigatran trials (1 THA, 2 TKA). Generally, riva-
roxaban trials followed a different statistical concept than 
dabigatran trials (tested both non-inferiority and superior-
ity hypotheses, whereas dabigatran trials were non-inferi-
ority trials) and had a shorter follow-up (Table 1). By set-
ting, the two groups of trials were largely similar in design. 
One rivaroxaban trial in THA (RECORD 1) (7) and the single 
dabigatran trial in this setting (RE-NOVATE) (11) employed 
the same standard mode of enoxaparin use, whereas the 
second rivaroxaban trial (RECORD 2) (8) used an atypically 
short enoxaparin treatment (Table 1). In TKA, one trial with 
each drug followed the European practice in enoxaparin 
use (1 × 40 mg/d) (RECORD 3 [9], RE-MODEL [12]) with a 
slightly shorter duration of treatment in the dabigatran 
trial (Table 1), whereas the other two followed the North 
American practice (2 × 30mg/d) (RECORD 4 ([10], RE-MO-
BILIZE [13]) (Table 1). All rivaroxaban trials concluded com-
parable safety and superior efficacy vs enoxaparin (Table 
1). All dabigatran trials concluded comparable safety vs 
enoxaparin. Two trials concluded non-inferior efficacy and 
Table 1. Pivotal efficacy/safety trials (multinational, randomized, double-blind) of rivaroxaban (R) and dabigatran etexilate (d) for 
prevention of venous thromboembolism after total hip (Tha) or knee (TKa) arthroplasty in comparison with enoxaparin sodium (e)*
Trial/ 
hypothesis setting
Test po + placebo
injection†












THA R 1 × 10 mg/d, 31-39 (33) days 
Start: 6-8 h after surgery
1 × 40 mg/d, 31-39 (34) days
Start: 12 h before surgery, 
then 6-8 h after
PP: R = 1537,
E = 1492
MITT: R = 1595, 
 = 1558
R = 2209, E = 2224
Follow-up 30-35 d 
after last dose
Efficacy: R>E
Safety: R = E
RECORD 2 (8) THA R 1 × 10 mg/d, 31-39 (34) days
Start: as above
1 × 40 mg/d, 10-14 (12) days
Start: as above
PP: R = 812,
E = 803
MITT: R = 864,
E = 869
R = 1228, E = 1229
Follow-up as above
Efficacy: R>E
Safety: R = E
RECORD 3 (9) TKA R 1 × 10 mg/d, 10-14 (12) days
Start: as above
1 × 40 mg/d, 10-14 (13) days
Start: as above
PP: R = 793,
E = 838
MITT: R = 824,
E = 878
R = 1220, E = 1239
Follow-up as above
Efficacy: R>E
Safety: R = E
RECORD 4 (10) TKA R 1 × 10 mg/d, 11-15 (11) days
Start: as above
2 × 30 mg/d 11-15 (11) days
Start: 12-24 h after surgery
PP: R = 864,
E = 878
MITT: R = 965,
E = 959
R = 1526, E = 1508
Follow-up as above
Efficacy: R>E




THA D1 1 × 220, D2 1 × 150 mg/d, 
28-35 (32, 33) days; Start: 1-4 h 
after surgery with 1/2 dose
1 × 40 mg/d, 28-35 (33) days
Start: 12 h before surgery, in 
some centers after surgery
MITT: D1 = 880,
D2 = 874,
E = 897
D1 = 1146, D2 = 1163, 
E = 1154; Follow-up 2 
mo after last dose
Efficacy: D1, 
D2 = E
Safety: D1, D2 = E
RE-MODEL (12) TKA D1 1 × 220, D2 1 × 150 mg/d, 6-
10 (8,8) days; Start: as above
1 × 40 mg/d, 6-10 (7) days
Start: as above
MITT: D1 = 503,
D2 = 526,
E = 512
D1 = 679, D2 = 703, 
E = 694; As above
Efficacy: D1, 
D2 = E
Safety: D1, D2 = E
RE-MOBILIZE (13) TKA D1 1 × 220, D2 1 × 150 mg/d, 
12-15 (14,14) days; Start: 6-12 h 
after surgery with 1/2 dose
2 × 30 mg/d, 12-15 (14) days
Start: 12-24 h after surgery
MITT: D1 = 604,
D2 = 649,
E = 643
D1 = 857, D2 = 871, 
E = 868; As above
Efficacy: D1, 
D2<E
Safety: D1, D2 = E
*abbreviations: po – orally; sc – subcutaneously; PP – per protocol; MiTT – modified intent-to-treat.
†scheduled and actual mean or median (bracketed) treatment duration is presented.
‡Rivaroxaban trials tested two efficacy hypotheses: non-inferiority (PP data) and superiority (MiTT data).
§dabigatran trials tested efficacy non-inferiority (MiTT for primary analysis, PP for secondary).
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one concluded inferior efficacy of dabigatran vs enoxapa-
rin (Table 1).
Definitions of primary and main secondary efficacy out-
comes were identical in rivaroxaban and dabigatran trials 
and implicated dependence on adjudication of venogra-
phy data (Table 2). Most of the events forming these two 
outcomes were actually asymptomatic (ie, detected sole-
ly on venograms) (7-13). Around 23% to 35% of patients 
across trials (and comparably by treatment arm per trial) 
who received treatment and underwent surgery were not 
evaluated for these outcomes since they lacked appropri-
ate venograms (7-13). Data on these two outcomes for the 
enoxaparin treatment arms (Table 2) clearly indicated the 
effect of factor “adjudication:” their incidence (and more so 
for the primary efficacy outcome) was much lower in riva-
roxaban than in dabigatran trials with similar designs (RE-
CORD 1 vs RE-NOVATE; RECORD 3 vs RE-MODEL; RECORD 4 
vs RE-MOBILIZE) (Table 2). Table 2 also indicates differences 
between European and North American-style enoxaparin 
use (RECORD 3 vs RECORD 4, RE-MODEL vs RE-MOBILIZE), 
and between “standard” and “short-term” enoxaparin use 
in THA (RECORD 1 vs RECORD 2). The major difference be-
tween the rivaroxaban and dabigatran trials, however, was 
the fact that the main bleeding outcome (“major bleeding”) 
in the rivaroxaban program did not include “surgical site” 
bleedings (Table 2). This is of relevance considering that sur-
gical site bleedings were by far the most prevalent bleed-
ings in each trial (7-13). This fact (likely with a contribution 
of adjudication) resulted in much lower bleeding rates for 
enoxaparin in rivaroxaban trials than in identically designed 
dabigatran trials (Table 2). These observations indicated in-
feasibility of indirect rivaroxaban vs dabigatran compari-
sons based on reported major efficacy/safety outcomes.
incidence of symptomatic VTe on treatment
Incidence of symptomatic VTE on treatment (DVT, PE, fatal or 
not) was comparable across enoxaparin arms in comparably 
designed rivaroxaban and dabigatran trials (Figure 1). Meta-
Table 2. Major efficacy and bleeding (safety) outcomes in pivotal trials of rivaroxaban and dabigatran for prevention of venous 
thromboemoblism (VTe) after total hip (Tha) or knee (TKa) arthroplasty: definitions and results for the enoxaparin (enoX) treatment 
arms. Rivaroxaban and dabigatran trials with similar design are aligned side by side*
outcomes/definitions enoX in Rivaroxaban trials† enoX in dabigatran trials† Ratio
Primary efficacy (composite)‡
Any DVT (symptomatic or not, proximal/distal), non-fatal PE, all-cause 
mortality
RECORD 1  3.72% RE-NOVATE 6.69% 0.56
RECORD 2  9.32% –
RECORD 3 18.9% RE-MODEL 37.7% 0.50
RECORD 4 10.1% RE-MOBILIZE 25.3% 0.40
Main secondary efficacy (composite)‡
Proximal DVT (symptomatic or not), non-fatal PE, VTE-related mortality 
on treatment
RECORD 1  1.97% RE-NOVATE 3.93% 0.50
RECORD 2  5.09% –
RECORD 3  2.59% RE-MODEL 3.52% 0.74
RECORD 4  1.98% RE-MOBILIZE 2.33% 0.85
Major bleeding on treatment§
RECORD trials. Fatal; into a critical organ; leads to reoperation; overt 
extra-surgical site (Hb fall ≥2 g/dL or requires ≥2 units blood). 
Dabigatran trials as above + leads to treatment discontinuation; overt 
surgical site bleedingII
RECORD 1  0.09% RE-NOVATE 1.56% 0.06
RECORD 2  0.08% –
RECORD 3  0.48% RE-MODEL 1.30% 0.37
RECORD 4  0.27% RE-MOBILIZE 1.38% 0.19
non-major, clinically relevant on treatment§
RECORD trials. Multiple source bleeding, spontaneous hematoma ≥25 
cm3, excessive wound hematoma.¶ Dabigatran trials. Spontaneous 
hematoma ≥25 cm3, wound hematoma ≥100 cm3, epistaxis >5 min, 
spontaneous hematuria or a prolonged one after intervention, sponta-
neous rectal bleeding, gingival bleeding >5 min or any other bleeding 
judged clinically relevant
RECORD 1  2.43% RE-NOVATE 3.47% 0.70
RECORD 2  2.69% –
RECORD 3  2.26% RE-MODEL 5.33% 0.42
RECORD 4  1.99% RE-MOBILIZE 2.42% 0.82
*abbreviations: dVT – deep venous thrombosis; Pe – pulmonary embolism; hb – hemoglobin; min – minutes.
†see Table 1 for trial details.
‡Modified-intent-to-treat population as a denominator.
§safety population (received at least one dose of study drug) as a denominator.
iiFollows eMea classification (21) but eMea includes surgical site bleedings requiring drainage /puncture as “major”. There is a major difference in 
definition vs rivaroxaban trials indicated in italics.
¶defined explicitly only in the ReCoRd 2 trial (8), but presumably used across the ReCoRd program and most likely embracing events largely similar 
to the definition used in dabigatran trials.
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analysis of rivaroxaban trials indicated that the risk of such 
events was slightly lower with rivaroxaban than with enoxa-
parin, but the difference did not attain statistical significance 
(Figure 1). The estimate is burdened with considerable incon-
sistency (high I2, significant Cochrane Q statistic), likely reflect-
ing different settings (difference was more in favor of rivaroxa-
ban in two trials in TKA [RECORD 3, RECORD 4] than in the trials 
in THA) (Figure 1). Meta-analysis of dabigatran trials indicated 
practically no difference between dabigatran and enoxparin 
(Figure 1). The estimate is also burdened with inconsistency 
likely due to a slight trend in favor of enoxaparin in the THA 
trial (RE-NOVATE) and a significant difference in favor of dabi-
gatran in one of the TKA trials (RE-MODEL) (Figure 1).
Indirect comparison of rivaroxaban vs dabigatran indicates 
no relevant difference between them: per 1000 patients 
treated with rivaroxaban instead of dabigatran, 3 additional 
would benefit by not experiencing symptomatic VTE, but 
the 95% CI extends from 13 who would benefit to 7 addi-
tional who would be harmed by experiencing it (Figure 1).
incidence of major or non-major clinically relevant 
bleeding on treatment
Incidence of major or non-major clinically relevant bleed-
ing (fatal or not) was fairly comparable across enoxaparin 
arms in comparably designed rivaroxaban and dabigatran 
trials (Figure 2), ie, differences were slight when compared 
with differences based on data in published reports (Table 
2) and likely represented differences in adjudication and/or 
slight differences in duration of the “on-treatment” periods. 
Meta-analysis of rivaroxaban trials consistently indicated a 
significantly higher risk of such bleedings with rivaroxaban 
than with enoxaparin: per 1000 patients treated with riva-
roxaban instead of enoxaparin, 10 more would have been 
harmed by experiencing them (95% CI, 3 to 17) (Figure 2). 
Meta-analysis of dabigatran trials consistently indicated 
practically no difference between dabigatran and enoxa-
parin in this respect (Figure 2). Indirect comparison be-
tween rivaroxaban and dabigatran indicates that per 1000 
patients treated with rivaroxaban instead of dabigatran, 10 
more would be harmed by experiencing such bleedings, 
and 95% CI extends from 24 who would be harmed to 4 
who would benefit by not experiencing them. The differ-
ence is of borderline significance (P = 0.085) (Figure 2).
Mortality
All-cause mortality during entire study periods was low 
for all treatments. All differences observed between riva-
roxaban or dabigatran and enoxaparin (based on SMRs) or 
between rivaroxaban and dabigatran (based on SRR; par-
Figure 1.
incidence of symptomatic venous thromboembolism on treatment (deep venous thrombosis, pulmonary embolism, regardless of the outcome) for pa-
tients who underwent surgery and received at least one dose of study drug. “on treatment:” between 1st dose and one day (rivaroxaban trials) or 3 days 
(dabigatran trials) after the last dose. Rivaroxaban and dabigatran trials with similar design are side by side.
*in ReCoRd 2 (4), treatment duration for rivaroxaban was 31-39 days (mean, 34) and for enoxaparin it was 10-14 days (mean, 12.4). events counted for the 
enoxaparin treatment arm were those recorded by day 14 (mean treatment duration +1 day).
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ticularly with correction for the difference in duration of 
follow-ups) could have been by chance (Table 3).
VTE-related mortality on treatment was very low for all 
treatments. Crude VTE-related mortality rate in dabiga-
tran-treated patients (5/5392 or 0.09%) was twice higher 
than the rates in enoxaparin-treated (0.045%) or rivaroxa-
ban-treated (0.05%) patients (Table 3). However, with an 
average rate of 4 such deaths per 8833 treatment periods 
(enoxaparin) or with an average rate of 3 deaths per 6132 
treatment periods (rivaroxaban), probabilities of observing 
5 or more deaths per 5392 treatment periods are 0.101 and 
0.127, respectively, and probabilities of observing 5 or few-
er deaths are 0.96 and 0.95, respectively. Accordingly, SMR 
and SRR did not indicate any difference between dabiga-
tran and enoxaparin or between rivaroxaban and dabiga-
tran that could not have been by chance (Table 3).
Only 3 deaths among 20 618 patients who constituted 
the overall safety population (received at least one dose 
of study drug) in the 7 trials were adjudicated as related to 
bleeding, none among enoxaparin-treated patients (Table 
3). Crude rate was twice higher for dabigatran-treated pa-
tients (2/5419 or 0.037%) than for rivaroxaban-treated pa-
tients (0.016%). Also, SRR (rivaroxaban/dabigatran) was <1 
but did not indicate a difference that could not have been 
by chance (Table 3). Indeed, with an average rate of 1 such 
death per 6183 treatment periods (rivaroxaban), probability 
of observing 2 or more deaths per 5419 treatment periods is 
0.16 and probability of observing 2 or fewer deaths is 0.94.
disCussion
The issue of thromboprophylactic strategy after THA/TKA is 
rather controversial for at least two reasons (3,24). First, the 
procedure should achieve an optimum balance between a 
benefit of avoiding DVT primarily because of the fear of PE 
and a harm of potential bleeding. In this respect, it should be 
noted that the association between DVT and PE in THA/TKA 
patients appears weaker than in some other populations 
at risk of DVT (eg, patients with thrombophilia, carcinoma, 
chronic heart failure). Hence, strategies used in these pa-
tients might not be automatically applicable to THA/TKA pa-
tients (3). Second, a meaningful weighing of benefit vs harm 
should include information about pre-existing risk factors 
for either VTE or for bleeding. Pivotal efficacy/safety trials of 
anticoagulants in THA/TKA settings (conducted primarily 
for regulatory purposes) usually do not provide such infor-
mation: patients with pre-existing bleeding tendency or 
risks factors for DVT are typically not enrolled, and this 
Figure 2.
incidence of major or non-major, clinically relevant bleeding on treatment (regardless of the outcome) for patients who received at least one dose of 
study drug. “on treatment:” between 1st dose and one day (rivaroxaban trials) or 3 days (dabigatran trials) after the last dose. Rivaroxaban and dabigatran 
trials with similar design are side by side.
*data include also surgical site bleeding (obtained from unpublished data [19,20], not included in published reports [7-10]). in ReCoRd 2 (8), events were 
counted up to 2 days after the last dose.
CLINICAL SCIENCES120 Croat Med J. 2010; 51: 113-23
www.cmj.hr
creates a gap between “clinical trial conditions” and “real life” 
(3,24). New oral anticoagulants rivaroxaban and dabigatran 
have valuable properties of simple oral dosing, predictive ef-
fects, and low potential for drug interactions. Overwhelmed 
with daily routine, practicing physicians might be prone to 
accept such convenient tools despite the actual uncertain-
ties about their real absolute and relative benefits or harms: 
these treatments yet need to be evaluated in respect to oth-
er available means, as well as in respect to each other (24).
In the absence of direct comparative trials, we attempted a 
formal indirect comparison between rivaroxaban and dab-
igatran based on their individual comparisons to enoxa-
parin (7-13). However, a comparison that would be based 
on major efficacy/safety outcomes reported in pivotal tri-
als was found infeasible due to differences in outcome 
definitions (bleeding events) and the apparent dif-
ferences in adjudication procedures (venography data). 
Therefore, other outcomes were identified that appeared 
appropriate for indirect comparisons in technical sense (in-
cidence of symptomatic VTE, incidence of major or non-
major clinically relevant bleeding, mortality), However, they 
might not have been fully illustrative of the treatments’ ef-
ficacy/safety profiles (at least not in regulatory terms) (21). 
Hence, the present analysis is only an exploratory effort. 
Within these limitations, several observations emerged re-
garding the relationship between rivaroxaban or dabiga-
tran and enoxaparin and between rivaroxaban and dabi-
gatran in prevention of VTE after THA/TKA.
Rivaroxaban vs enoxaparin
In each of the four individual trials (7-10) with overall 12 400 
patients, rivaroxaban was found superior to enoxaparin in 
Table 3. Mortality outcomes in pivotal rivaroxaban and dabigatran trials by treatment and setting (total hip [Tha] or knee [TKa] 
arthroplasty). see Table 1 for trial details. number of deaths (n) is given per number of patients (n) which equals the number of 
person-time units*
Mortality outcomes Rivaroxaban dabigatran enoxaparin
all-cause mortality (during study)†
THA cumulative n/N (person-time)  7/3437 (0.20%)  8/2309(0.35%) 14/4607 (0.30%)
TKA cumulative n/N (person-time)  6/2746 (0.22%)  8/3110 (0.26%) 18/4309 (0.42%)
Total 13/6183 (0.21%) 16/5419 (0.29%) 32/8916 (0.36%)
SMR (95% CI)  0.60 (0.32-1.02)  0.80 (0.46-1.30)
SMR rivarox/SMR dabig (95% CI)  0.75 (0.33-1.65)
SRR rivarox/dabig (95% CI)  0.70 (0.33-1.45)
all-cause mortality, follow-up corrected‡
THA  8.75/3437  8/2309 17.25/4607
TKA  7.5 /2746  8/3110 21/4309
SMR (95% CI)  0.62 (0.36-1.06)  0.67 (0.39-1.09)
SMR rivarox/SMR dabig (95% CI)  0.92 (0.44-1.96)
SRR rivarox/dabig (95% CI)  0.87 (0.43-1.74)
Pe/dVT-related death on treatment§
THA cumulative n/N (person-time)  2/3405 (0.06%)  3/2293 (0.13%)  3/4555 (0.07%)
TKA cumulative n/N (person-time)  1/2727 (0.04%)  2/3099 (0.06%)  1/4278 (0.02%)
Total  3/6132 (0.05%)  5/5392 (0.09%)  4/8833 (0.045%)
SMR (95% CI)  1.09 (0.22-3.18)  2.06 (0.67-4.81)
SMR rivarox/SMR dabig (95% CI)  0.53 (0.08-2.72)
SRR rivarox/dabig (95% CI)  0.49 (0.12-2.06)
bleeding-related death on treatment§
THA cumulative n/N (person time)  0/3437  2/2309 (0.09%)  0/4607
TKA cumulative n/N (person time)  1/2746 (0.04%)  0/3110  0/4309
Total  1/6183 (0.016%)  2/5419(0.037%)  0/8916
SRR rivarox/dabig (95% CI)  0.39 (0.04-4.34)
*abbreviations: Pe – pulmonary embolism; dVT – deep venous thrombosis; sMR – standardized mortality ratio; Ci – confidence interval; sRR – stan-
dardized rate ratio.
†between 1st dose of study drug and the end of follow-up. Follow-up was 2 mo in dabigatran trials vs 30-35 d in rivaroxaban trials.
‡Correction for the difference in duration of follow-up, see Materials and Methods.
§between 1st and last dose +1 d (rivaroxaban trials) or +3 d (dabigatran trials).
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efficacy and comparable in safety. The present analysis 
suggests that these conclusions might somewhat over-
estimate the benefit and underestimate potential harms 
of rivaroxaban vs enoxaparin. Rivaroxaban was associated 
with a lower risk of symptomatic VTE (DVT with or with-
out PE, fatal or not) than enoxaparin. Although the differ-
ence did not attain statistical significance in the present 
analysis (benefit per 1000 patients = 4 [95% CI, 9 benefit 
to 1 harm]), data do suggest that there is a true (popula-
tion) difference in favor of rivaroxaban. The middle 50% of 
CI around benefit per 1000 patients (which are most likely 
to contain the true difference) extend from 2 benefit to 7 
benefit, and difference between the treatments most like-
ly would have been significant had there been more tri-
als. However, the size of the difference is small and it does 
not seem likely that additional trials would meaningfully 
change the point estimate. At the same time, treatment 
with rivaroxaban clearly increases the risk of major or non-
major clinically relevant bleeding and present results are 
in agreement with the analysis conducted by FDA (regres-
sion-based individual patient data meta-analysis) (20). Ac-
cording to present analysis, there is a numerically negative 
trade-off between a benefit (avoiding symptomatic VTE) 
and harm (major or clinically relevant bleeding) for rivar-
oxaban relative to enoxaparin: per 1000 treated patients, it 
conveys the benefit of 4 (up to 9) additional patients who 
avoid symptomatic VTE and the harm of 10 (95% CI, 3 to 
17) additional patients who experience bleeding, ie, for 
each patient who would benefit from switching to rivar-
oxarban, 2-3 would be harmed. Mortality data (all-cause, 
VTE-related, bleeding-related) for rivaroxaban and enoxa-
parin are too scarce to make any meaningful conclusion, 
primarily due to low event rates. However, at this point it 
seems plausible to conclude that one should not expect 
any practically relevant benefit or harm from rivaroxaban 
in this respect.
dabigatran vs enoxaparin
In two out of three pivotal trials (11,12) with overall 8150 
patients, dabigatran showed non-inferior efficacy and 
comparable safety to enoxaparin, whereas in one (13) 
it was comparable in safety but failed, albeit by a small 
amount, in a formal efficacy non-inferiority test (for the pri-
mary efficacy outcome) against the North American-style 
enoxaparin regimen. In the present analysis, dabigatran 
was fully comparable to enoxaparin regarding the inci-
dence of symptomatic VTE and incidence of major or non-
major clinically relevant bleeding, providing no additional 
benefit (avoiding VTE) and no additional harm (bleeding). 
Mortality data are too scarce for a meaningful conclusion. 
At this point, they do not seem to indicate that one should 
expect any particular benefit or harm from dabigatran rela-
tive to enoxaparin in this respect.
Rivaroxaban vs dabigatran
Indirect comparisons have low power. One randomized 
trial is as precise as an indirect comparison based on four 
randomized trials of the same size, or in other words, four 
times as many similarly sized trials are needed for the 
indirect approach to have the same power as directly 
randomized comparisons (17). Having this in mind, the 
present data suggest that the trade-off between benefit 
(avoiding symptomatic VTE) and harm (major or non-ma-
jor clinically relevant bleeding) numerically disfavors riva-
roxaban as compared with dabigatran. Regarding the in-
cidence of symptomatic VTE, risk difference between the 
two drugs indicates a small and insignificant (P = 0.275) 
difference (benefit) in favor of rivaroxaban (benefit per 
1000 patients 3 [95% CI, 13 benefit to 7 harm]). The mid-
dle 50% of the CI also extend from benefit to harm (8 ben-
efit to 2 harm) and it does not seem likely that the entire 
95% CI around the point-estimate would have been con-
tained within the “benefit area” even with additional trials. 
At the same time, risk difference regarding major or non-
major clinically relevant bleeding indicates a difference 
(harm) that disfavors rivaroxaban (harm per 1000 patients 
10 ([95% CI, 24 harm to 4 benefit]) and which, although 
of borderline significance (P = 0.085), does indicate a true 
(population) difference between treatments. Namely, the 
middle 50% of the CI extend from 3 harm to 17 harm, and 
the difference most likely would have been significant 
had there been more trials. Hence, switching from dabi-
gatran to rivaroxaban does not seem likely to confer the 
benefit of additional patients avoiding symptomatic VTE, 
but it seems likely to confer the harm of additional pa-
tients experiencing bleeding. The “best-case” scenarios fa-
voring one or the other drug (based on “beneficial” limits 
of the 95% CI of the present estimates) also illustrate the 
benefit-harm trade-off in favor of dabigatran. In the best-
case scenario favoring rivaroxaban, per 1000 patients 
treated with rivaroxaban instead of dabigatran, 13 more 
would benefit by not experiencing symptomatic VTE and 
4 additional would benefit by not experiencing bleeding. 
Conversely, in the “best-case” scenario favoring dabiga-
tran, per 1000 patients treated with dabigatran instead 
of rivaroxaban, 7 more would benefit by not experienc-
ing symptomatic VTE and 24 more would benefit by 
not experiencing bleeding.
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Due to the low observed event rates, mortality data are too 
scarce to make finite conclusions. The few more VTE-relat-
ed and bleeding-related deaths among dabigatran-treated 
than among rivaroxaban-treated patients could have been 
by chance and do not disqualify dabigatran in compari-
son with rivaroxaban, particularly as they were subsumed 
within symptomatic VTE and major or non-major clinically 
relevant bleeding, respectively.
ConClusion
Rivaroxaban and dabigatran are newly available drugs 
competing for a market share in the setting of thrombo-
prohylaxis after THA/TKA. Practicing physicians are likely 
to be exposed to a considerable “marketing pressure.” Al-
though accepted as effective and safe for the purpose, it 
should be noted that both drugs yet need to be fully eval-
uated in respect to other available means. As for the rela-
tionship between the two, the present analysis suggests 
that the existing clinical data do not provide grounds for 
any claims about superiority of one over the other drug. 
This, of course, does not mean that they should be per-
ceived as “therapeutic equivalents” – evidence of that is 
also missing. Hence, direct comparative trials of rivaroxa-
ban vs dabigatran in this setting are needed.
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